GlassScriptPhysician profile
Rohn C Rigby
NPI 1437283553
$5,290.15
in general payments reported to CMS, 2019-2025
32 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $398 · 2021: $401 · 2022: $339 · 2023: $379 · 2024: $828 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,130 · Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,130.00 |
| Food and Beverage | $1,409.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,203.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $401.82 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $386.95 | 2019-2025 | Farxiga |
| Corcept Therapeutics | $296.00 | 2022-2025 | Korlym |
| Abbvie INC. | $213.67 | 2021-2024 | Vraylar |
| Abbott Laboratories | $154.59 | 2020-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $104.47 | 2019-2020 | |
| Kvk-Tech, INC. | $48.85 | 2024 | |
| Dexcom, INC. | $44.87 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $44.32 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $37.77 | 2024-2025 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.36 | 2019-2020 | |
| Strongbridge US INC. | $31.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.21 | 2019 | |
| Glaxosmithkline, LLC. | $24.99 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.88 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.97 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.16 | 2024 | Recorlev |
| Genentech USA, INC. | $16.68 | 2019 | |
| Exeltis, USA INC. | $15.67 | 2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $14.12 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.08 | 2019 | |
| Merck Sharp & Dohme LLC | $13.39 | 2020 | |
| Currax Pharmaceuticals LLC | $13.00 | 2022 | |
| Pfizer INC. | $12.25 | 2019 | |
| Shire North American Group INC | $12.19 | 2019 | |
| Bolton Medical INC | $12.12 | 2019 | |
| Amgen INC. | $11.96 | 2019 | |
| Optinose US, INC. | $11.35 | 2021 | |
| Janssen Biotech, INC. | $11.25 | 2019 | |
| Neuronetics, INC. | $9.31 | 2019 | |
| Clarus Therapeutics INC. | $4.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohn Rigby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.